GlassScriptPhysician profile
Diep H Vuong
NPI 1114371028
$5,017.23
in general payments reported to CMS, 2019-2025
13 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 78% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $223 · 2021: $431 · 2022: $1,591 · 2023: $530 · 2024: $313 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711 · Travel and Lodging: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.99 |
| Travel and Lodging | $1,060.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,432.77 | 2025 | |
| Boston Scientific Corporation | $1,108.27 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept |
| Medtronic, INC. | $1,100.05 | 2021-2022 | |
| Painteq LLC | $381.58 | 2022-2024 | Painteq |
| Abbott Laboratories | $250.30 | 2024-2025 | Eterna, Proclaim |
| Spinal Simplicity, LLC | $183.57 | 2022-2024 | Ha Minuteman G3-R |
| International Rehabilitative Sciences, INC | $155.22 | 2025 | Rs-4i Plus With Intersperse, Rs-Lbg, Rs-Fbg, Rs-Sg |
| Merz North America, INC. | $150.00 | 2020 | |
| Saluda Medical Americas, INC. | $137.34 | 2023 | Evoke Scs |
| Mml US, INC. | $43.18 | 2025 | Reactiv8 |
| Averitas Pharma INC. | $30.99 | 2025 | Qutenza |
| Biotronik Nro, INC. | $28.73 | 2025 | Prospera |
| Electronic Waveform Lab, INC. | $15.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diep Vuong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.